ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > Protein > EGFRvIII > EGI-H5255

Human EGFRvIII Protein, Fc Tag (MALS verified)

  • Synonym
    EGFRvIII
  • Source
    Human EGFRvIII, Fc Tag(EGI-H5255) is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Ser 378 (Accession # NP_001333870.1).
    Predicted N-terminus: Leu 25
  • Molecular Characterization
    EGFRvIII Structure

    This protein carries a human IgG1 Fc tag at the C-terminus

    The protein has a calculated MW of 65.1 kDa. The protein migrates as 90-100 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >95% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
EGFRvIII SDS-PAGE

Human EGFRvIII, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-MALS
EGFRvIII MALS images

The purity of Human EGFRvIII, Fc Tag (Cat. No. EGI-H5255) is more than 90% and the molecular weight of this protein is around 150-184 kDa verified by SEC-MALS.

Bioactivity-ELISA
 EGFRvIII ELISA

Immobilized Human EGFRvIII, Fc Tag (Cat. No. EGI-H5255) at 2 μg/mL (100 μL/well) can bind Anti-EGFRvIII Antibody, Human IgG1 with a linear range of 0.1-8 ng/mL (QC tested).

  • Background
    The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer.
    The type III EGF deletion mutant receptor (EGFRvIII) is the most common mutation and was first identified in primary human glioblastoma tumors. This tumor-specific antigen is ligand-independent, contains a constitutively active tyrosine kinase domain, and has been shown to be present in a number of human malignancies. EGFRvIII has been selected as a target for CAR-modified T-cell studies in recent years.
  • Clinical and Translational Updates

コメント (0)


ETD of in-stock products: 4 business days

価格(JPY) : 114,800

価格(JPY) : 677,600

プロモーション&展示



医薬品開発状況

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:13 Details
  • Latest Research Phase:Phase 2 Clinical

データシート&ドキュメンテーション

DMF請求
DMF (Drug Master File)

関連製品一覧

新製品

お問い合わせ&コメント

This web search service is supported by Google Inc.

totopphone